Atara Biotherapeutics 8-K: Exit Costs, Officer Comp Changes

Ticker: ATRA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1604464

Atara Biotherapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAtara Biotherapeutics, INC. (ATRA)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001, $4.5 million, $3,000 m, $200, $185,000
Sentimentmixed

Complexity: simple

Sentiment: mixed

Topics: restructuring, executive-compensation, corporate-governance, disposal-activities

TL;DR

**Atara Biotherapeutics filed an 8-K detailing exit costs and officer compensation changes, signaling potential restructuring.**

AI Summary

Atara Biotherapeutics, Inc. filed an 8-K on January 8, 2024, reporting on costs associated with exit or disposal activities, changes in officers' compensatory arrangements, and other events. This filing indicates potential restructuring or strategic shifts within the company, which could impact future financial performance and operational efficiency. Investors should pay attention to the details of these changes as they may signal efforts to streamline operations or adapt to market conditions, potentially affecting the stock's long-term value.

Why It Matters

This filing signals potential operational restructuring and changes in executive compensation, which could affect the company's financial health and strategic direction. These changes might lead to improved efficiency or reflect challenges the company is addressing.

Risk Assessment

Risk Level: medium — The filing mentions 'Cost Associated with Exit or Disposal Activities,' which could indicate significant operational changes or asset divestitures that carry both potential benefits and risks.

Analyst Insight

Investors should monitor future filings for specific details regarding the 'exit or disposal activities' and the nature of changes to 'compensatory arrangements of certain officers' to understand the financial impact and strategic direction of Atara Biotherapeutics. This could indicate a shift in focus or a move to improve efficiency.

Key Players & Entities

FAQ

What specific items were reported in this 8-K filing by Atara Biotherapeutics, Inc.?

The 8-K filing by Atara Biotherapeutics, Inc. on January 8, 2024, reported on 'Cost Associated with Exit or Disposal Activities,' 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers,' 'Regulation FD Disclosure,' 'Other Events,' and 'Financial Statements and Exhibits'.

What is the earliest event date reported in this 8-K filing?

The earliest event reported in this 8-K filing is January 8, 2024.

What is the business address of Atara Biotherapeutics, Inc. as stated in the filing?

The business address of Atara Biotherapeutics, Inc. is 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California, 91320.

What is the telephone number for Atara Biotherapeutics, Inc. according to the filing?

The telephone number for Atara Biotherapeutics, Inc. is (805) 623-4211.

Under which SEC Act was this 8-K filed?

This 8-K was filed under the 1934 Act.

Filing Stats: 1,021 words · 4 min read · ~3 pages · Grade level 11.3 · Accepted 2024-01-08 08:11:30

Key Financial Figures

Filing Documents

05

Item 2.05 Costs Associated with Exit or Disposal Activities. On January 8, 2024, Atara Biotherapeutics, Inc. (the "Company") announced a reduction in its workforce that will impact approximately 25% of its current employees. The Company expects to substantially complete the workforce reduction by May 2024. The Company expects to recognize approximately $4.5 million in total for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash charges. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction. Additional details will be provided in the Company's Quarterly Report on Form 10-Q for the period ending March 31, 2024.

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 8, 2024, the Company announced that the employment of Manher (AJ) Joshi, the Company's Executive Vice President, Chief Medical Officer, would terminate effective as of February 2, 2024. Pursuant to the terms of the Executive Employment Agreement dated as of November 10, 2020 between Dr. Joshi and the Company, Dr. Joshi will be entitled to receive severance benefits of 12 months of base salary continuation and, subject to his timely election of coverage, payment by the Company of up to 12 months of continued health care benefits. In connection with Dr. Joshi's departure from the Company and subject to his execution of a general release in favor of the Company, the Company intends to enter into a consulting agreement with Dr. Joshi pursuant to which Dr. Joshi will provide consulting services to the Company through January 31, 2025. Dr. Joshi is expected to be paid a consulting fee of $3,000 monthly for up to a specified number of consulting hours per month and is expected to receive additional compensation of $200 per hour in excess of such specified number of consulting hours. Dr. Joshi's outstanding restricted stock unit equity awards will continue to vest during the consulting term. In addition, Dr. Joshi will be entitled to receive $185,000 upon the approval by the United States Food and Drug Administration of a biologics license application for tabelecleucel.

01

Item 7.01 Regulation FD Disclosure. The Company intends to conduct meetings with securities analysts, investors and others in connection with the 42nd Annual J.P. Morgan Healthcare Conference beginning on January 8, 2024. As part of these meetings, the Company intends to utilize the corporate slide presentation furnished with this Current Report on Form 8-K as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 hereto, is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 hereto will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

01

Item 8.01 Other Events. On January 8, 2024, the Company issued a press release titled "Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference." A copy of the Company's press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Slide Presentation, dated January 8, 2024 99.2 Atara Biotherapeutics, Inc. Press Release, dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATARA BIOTHERAPEUTICS, INC. Date: January 8, 2024 By: /s/ Eric Hyllengren Eric Hyllengren Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing